Shea, Lauren K.
Honjo, Kazuhito
Redden, David T.
Tabengwa, Edlue
Li, Ran
Li, Fu-Jun
Shakhmatov, Mikhail
Chiorazzi, Nicholas
Davis, Randall S. http://orcid.org/0000-0003-1906-8219
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA161731 and CA131656)
University of Alabama at Birmingham (CLL and Cancer Immunobiology Programs)
U.S. Department of Health & Human Services | National Institutes of Health (RR026935)
Leukemia and Lymphoma Society
Article History
Received: 7 December 2018
Revised: 11 March 2019
Accepted: 20 March 2019
First Online: 15 May 2019
Conflict of interest
: R.S.D. has previously filed a patent (US 20100285007A1) related to FCRL2 in CLL prognostication. The remaining authors declare that they have no conflict of interest.